跳至主要内容
临床试验/ACTRN12614000478617
ACTRN12614000478617进行中(未招募)2 期

Assessing the feasibility of Stereotactic Ablative Body Radiotherapy (SABR) for stage I Non-Small Cell Lung Cancer (NSCLC): A single arm prospective phase II non-randomized multicentre study

Dr Eric Hau0 个研究点目标入组 134 人开始时间: 2014年5月8日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
134

研究概览

简要总结

Collaborative Implementation of Stereotactic Ablative Body Radiotherapy - A model for the safe implementation of complex radiotherapy techniques in Australia

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Diagnosis of non-small cell lung cancer
  • -Pathological diagnosis is desirable where this can be achieved.
  • -Diagnosis based on imaging: requires evidence that lesion(s) are increasing in size on 2 consecutive CT scans and /or increased uptake on PET.
  • Stage T1-T2, N0M0 (AJCC Staging, 6th ed.) with tumour size less than or equal to 5 cm, based upon:
  • -History and physical examination 4 weeks prior to registration.
  • -CT chest, abdomen and pelvis and/or
  • -FDG PET-CT scan
  • ECOG performance status of less than or equal to 2
  • Patients must be able to lie flat and comply with the requirements of simulation and treatment.
  • Patients with previous thoracic radiotherapy are permitted, provided V20 less than 15% on previous treatment an no overlap with intended current radiotherapy field
  • Patients with previous history of malignancy may be included provided the previous malignancy is in remission and after a MDT discussion the current lung lesion is thought to be more likely of lung primary rather than metastatic disease

排除标准

  • Pregnant women
  • Inability to lie flat and tolerate immobilization for duration of planning and treatment

研究者

发起方
Dr Eric Hau

相似试验